This week, which stocks lagged or dragged? Weekly Winners column keeps up with market trends, helping Tigers sort out the week's hottest sectors, stock winners and important news.

Below are top 10 S&P 500 stock gainers for the week ended July 25:

West Pharmaceutical Soars on Upbeat Results, Guidance Raise

West Pharmaceutical shares soared 25% as the company reported its second-quarter results above estimates and raised full-year guidance, backed by strong demand for GLP-1 elastomer products.

The company reported quarterly revenue of $766.5M, up 9.2% year-on-year, beating estimates of $726.1M. It also posted adjusted profit of $1.84 per share, above analysts' consensus of $1.51 per share.

The company raised its full year 2025 revenue outlook to a range between $3.04B and $3.06B, above previous guidance of $2.945B to $2.975B.

Lamb Weston Leaps After Topping Estimates, Setting Solid Guidance

Lamb Weston Holdings rallied 24.2% this week after topping expectations with its FQ4 earnings report.

CEO Mike Smith noted Lamb Weston returned to growth in the second half of the year with momentum in customer wins and retention.

Sales improved 4.3% year-over-year to $1.68 billion for the quarter that ended on May 25. Volume increased 8% compared to the prior year quarter due in part to contract wins across each of the company’s channels and geographic regions. The increase was partially offset by soft global restaurant traffic trends, which declined low single-digits in the U.S. and UK, the company’s largest global markets, compared with the prior year quarter. Price/mix declined 4 percent, reflecting efforts by Lamb Weston (NYSE:LW) to partner with customers on price and trade to compete in the increasingly competitive environment in both the North America and International segments.

Iqvia Bolts Higher After A Surprise Segment Beat Saved Its Second Quarter

Iqvia shares surged 24% this week as the contract research firm raised its outlook for the year on the back of unexpected strength from its technology and analytics business.

Iqvia's second-quarter sales rose 2.3% on a strict, as-reported basis to $3.81 billion. In constant currency, sales rose 3.5%. The top line beat forecasts for $3.78 billion to $3.79 billion, Smock said. Adjusted earnings were $2.64 per share, up 8.6% year over year and above calls for $2.57 a share, according to FactSet.

Iqvia raised its sales outlook for the year by $25 million at the midpoint. The company now expects about $15.43 billion to $15.53 billion in sales. Iqvia also guided to adjusted earnings of $11.10 to $11.30 a share this year. That's an increase of 10 cents at the midpoint from its previous guidance.

TE Connectivity Stock Jumps. Earnings Show That Managing Tariffs Can Be Easy

Electrical components supplier TE Connectivity reported better-than-expected fiscal third-quarter sales and earnings. Guidance for the coming quarter also topped Wall Street projections. The shares jumped 16.3% this week.

TE Connectivity reported Wednesday adjusted fiscal third-quarter earnings per share of $2.27 from sales of $4.5 billion. That tops its guidance for earnings of $2.06 and sales of $4.3 billion. Wall Street was projecting profit of $2.10 a share and sales of $4.3 billion.

For the fourth fiscal quarter, TE expects to generate earnings of $2.27 a share from sales of almost $4.6 billion. That’s better than current analyst projections of $2.14 and $4.4 billion, respectively.

Baker Hughes Jumps on Q2 Beat Propelled by Orders for Data Center Equipment

Baker Hughes shares jumped 15.9% this week after reporting better than expected Q2 adjusted earnings and revenues, highlighted by strong growth in orders for data center equipment and natural gas infrastructure.

Q2 profit climbed to $701M, or $0.71/share, from $579M, or $0.58/share, in the year-earlier quarter, and while revenues fell 3% Y/Y to $6.91B, the result topped analyst consensus, and the quarter was paced by a 5% boost in sales at the company's industrial and energy technology unit to $3.29B, sparked by strong order momentum supported by data center-related orders; sales in the oilfield services and equipment segment fell 10% to $3.62B.

Overall Q2 orders totaled $7.03B, up 9% Q/Q and down 7% Y/Y.

Thermo Fisher Gains as Revised Outlook Follows Q2 Beat

Shares of Thermo Fisher Scientific gained 15.3% this week after the company, following its Q2 2025 results, raised the lower end of its full-year outlook to remain in line with the consensus.

Earlier in the day, the Waltham, Massachusetts-based healthcare giant topped Street forecasts for Q2 2025, thanks mainly to its divisions, Life Sciences Solutions and Lab Products & Biopharma Services.

During the earnings call, CEO Marc Casper announced that his company expects to add $43.6B - $44.2B in revenue this year, compared to its prior forecast of $43.3B - $44.2B in April and in line with $43.7B projected by analysts.

Deckers Shares Soar on Rising Demand for Hoka, UGG Footwears in China, Europe

Deckers Outdoor beat first-quarter revenue and profit estimates on resilient demand for its sneakers and boots in international markets, sending the shares of the Hoka parent surging 14.7% this week.

Solid demand for Hoka shoes and UGG boots in Europe and China shielded Deckers from the impact of tariff-related concerns and sticky inflation on consumer spending in the U.S., its largest market by revenue.

International market sales nearly doubled from a year ago, benefiting from the company opening its own stores in China and Europe.

Charles River Laboratories' Shares Surge Amid New Plasmid DNA Agreement

Shares of lab services company Charles River Laboratories jumped 14.5% this week after the company announced a plasmid DNA manufacturing agreement with Elly's Team, a parent-led foundation working to find a cure for a rare genetic disorder.

The contract development and manufacturing organization (CDMO) agreement involved producing critical materials for a Phase I clinical trial targeting a neurodevelopmental disorder known as NEDAMSS. This partnership was part of Charles River's Cell and Gene Therapy Accelerator Program, which provides gene therapy CDMO capabilities and advisory services. The news highlighted the company's expanding role in the advanced therapies market, a high-growth area within the biopharmaceutical industry. By supporting the development of potentially curative treatments for ultra-rare diseases, Charles River showcased its specialized manufacturing capabilities, which likely bolstered investor confidence in its long-term growth prospects.

Gold Miner Newmont's Quarterly Profit Beats Estimates as Bullion Rallies

Newmont surpassed Wall Street expectations for second-quarter profit as the world's top gold miner benefited from a rally in bullion prices, sending its shares 13% higher this week.

Prices of the precious metal have consistently set record highs over the past few quarters, as uncertainty over U.S. President Donald Trump's tariff plans and geopolitical concerns boosted gold's safe-haven appeal.

On an adjusted basis, the miner posted a profit of $1.43 per share for the three months ended June 30, compared with analysts' average estimate of $1.18 per share, according to data compiled by LSEG.

Earlier this week, the company said three workers were trapped underground at a western Canadian mine operated by Newmont, adding that operations had been temporarily suspended at the mine.